Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.47
(-2.97%)
USD 1.47
(-2.97%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.22 Million USD | -33.33% |
| 2022 | 60.33 Million USD | 12.0% |
| 2021 | 53.87 Million USD | 62.58% |
| 2020 | 33.13 Million USD | 16.73% |
| 2019 | 28.38 Million USD | -53.04% |
| 2018 | 60.44 Million USD | 196.98% |
| 2017 | 20.35 Million USD | 208.6% |
| 2016 | 6.59 Million USD | 324.12% |
| 2015 | 1.55 Million USD | 7.17% |
| 2014 | 1.45 Million USD | 295.37% |
| 2013 | 367 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 27.24 Million USD | -14.98% |
| 2024 Q1 | 32.05 Million USD | -24.36% |
| 2023 Q2 | 55.89 Million USD | 5.68% |
| 2023 Q1 | 52.89 Million USD | -12.33% |
| 2023 FY | 42.37 Million USD | -29.77% |
| 2023 Q4 | 42.37 Million USD | -31.68% |
| 2023 Q3 | 62.02 Million USD | 10.95% |
| 2022 Q2 | 42.22 Million USD | -8.86% |
| 2022 Q1 | 46.32 Million USD | -14.0% |
| 2022 Q3 | 47.79 Million USD | 13.19% |
| 2022 FY | 60.33 Million USD | 12.0% |
| 2022 Q4 | 60.33 Million USD | 26.24% |
| 2021 FY | 53.87 Million USD | 62.58% |
| 2021 Q2 | 54.23 Million USD | 10.44% |
| 2021 Q1 | 49.1 Million USD | 48.2% |
| 2021 Q4 | 53.87 Million USD | 14.83% |
| 2021 Q3 | 46.91 Million USD | -13.49% |
| 2020 Q2 | 35.63 Million USD | -7.77% |
| 2020 FY | 33.13 Million USD | 16.73% |
| 2020 Q4 | 33.13 Million USD | 6.39% |
| 2020 Q3 | 31.14 Million USD | -12.6% |
| 2020 Q1 | 38.63 Million USD | 36.12% |
| 2019 Q4 | 28.38 Million USD | -62.22% |
| 2019 Q3 | 75.14 Million USD | -6.08% |
| 2019 Q2 | 80 Million USD | 12.8% |
| 2019 Q1 | 70.93 Million USD | 17.35% |
| 2019 FY | 28.38 Million USD | -53.04% |
| 2018 Q4 | 60.44 Million USD | 171.28% |
| 2018 FY | 60.44 Million USD | 196.98% |
| 2018 Q1 | 13.82 Million USD | 8.31% |
| 2018 Q2 | 20.06 Million USD | 45.19% |
| 2018 Q3 | 22.28 Million USD | 11.02% |
| 2017 Q2 | 8.36 Million USD | 48.47% |
| 2017 FY | 20.35 Million USD | 208.6% |
| 2017 Q4 | 12.76 Million USD | 27.71% |
| 2017 Q1 | 5.63 Million USD | -9.42% |
| 2017 Q3 | 9.99 Million USD | 19.4% |
| 2016 FY | 6.59 Million USD | 324.12% |
| 2016 Q4 | 6.22 Million USD | 35.55% |
| 2016 Q3 | 4.59 Million USD | -16.63% |
| 2016 Q2 | 5.5 Million USD | 47.68% |
| 2016 Q1 | 3.72 Million USD | 139.81% |
| 2015 Q2 | 1.42 Million USD | 0.0% |
| 2015 Q3 | 1.89 Million USD | 33.22% |
| 2015 Q4 | 1.55 Million USD | -18.03% |
| 2015 FY | 1.55 Million USD | 7.17% |
| 2015 Q1 | - USD | -100.0% |
| 2014 Q4 | 1.45 Million USD | 0.0% |
| 2014 FY | 1.45 Million USD | 295.37% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 367 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 93.554% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 68.1% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 93.488% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 84.805% |
| bluebird bio, Inc. | 424.62 Million USD | 90.527% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 41.497% |
| Imunon, Inc. | 8.53 Million USD | -371.559% |
| Editas Medicine, Inc. | 150.05 Million USD | 73.193% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.804% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.852% |
| Myriad Genetics, Inc. | 312.9 Million USD | 87.144% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.054% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 91.748% |
| Verastem, Inc. | 71.18 Million USD | 43.491% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.942% |
| Waters Corporation | 3.47 Billion USD | 98.843% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.922% |
| Biogen Inc. | 12.04 Billion USD | 99.666% |
| Nektar Therapeutics | 267.04 Million USD | 84.937% |
| Perrigo Company plc | 6.04 Billion USD | 99.334% |
| Dynavax Technologies Corporation | 375.02 Million USD | 89.274% |
| Illumina, Inc. | 4.36 Billion USD | 99.079% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -14.353% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 79.449% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 84.316% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -7.868% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.872% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 51.202% |
| Evolus, Inc. | 209.68 Million USD | 80.816% |
| Adicet Bio, Inc. | 37.12 Million USD | -8.367% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.434% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 93.912% |
| FibroGen, Inc. | 585.72 Million USD | 93.132% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.182% |
| OPKO Health, Inc. | 622.47 Million USD | 93.538% |
| Homology Medicines, Inc. | 118.53 Million USD | 66.063% |
| Geron Corporation | 146.12 Million USD | 72.472% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.007% |
| Exelixis, Inc. | 678.44 Million USD | 94.071% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -100.419% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -220.935% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 83.961% |
| Zoetis Inc. | 9.29 Billion USD | 99.567% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 89.874% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 18.2% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.219% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 16.966% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.455% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.328% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 64.964% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.561% |
| Blueprint Medicines Corporation | 918.64 Million USD | 95.621% |
| Insmed Incorporated | 1.66 Billion USD | 97.579% |
| TG Therapeutics, Inc. | 169.08 Million USD | 76.21% |
| Incyte Corporation | 1.59 Billion USD | 97.474% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 96.607% |